To include your compound in the COVID-19 Resource Center, submit it here.

Acorda reports Ampyra revenues

Acorda Therapeutics Inc. (NASDAQ:ACOR) reported $51.8 million in 2Q11 sales

Read the full 103 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE